降尿酸治疗对老年2～5期慢性肾脏病合并高尿酸血症患者肾功能的影响

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of uric acid lowering therapy on renal function in elderly patients with 2-5 stage chronic kidney disease with hyperuricemia.Methods According to the patient′s glomerular filtration rate(GFR),110 patients with stage 2 to 5 chronic kidney disease and hyperuricemia who were treated in our hospital from January 2019 to January 2020 were selected and divided into group A (74 cases),GFR value was between 30-89 ml/min(60-89 ml/min was stage 2,30-59 ml/min was stage 3) and group B (36 cases),GFR value was between 0-29 ml/min(15-29 ml/min was 4 stages,<15 ml/min was 5 stages,according to GFR value.Both groups were treated with Febuxostat.The blood uric acid (SUA) attainment rate was compared between the two groups.the changes in renal kinetic energy (blood creatinine [SCr],SUA,urea nitrogen [BUN]) before and after treatment and adverse drug reactions in all patients were compared between the two groups Results After 6 months of treatment,the uric acid lowering compliance rate of both groups was above 90% (P＞0.05);after treatment,the levels of SCr,SUA,and BUN at each time point in groups A and B decreased,and the improvement effect of group A was better (P<0.05).Conclusion Febuxostat has a good effect on the treatment of stage 2-3 chronic kidney disease with hyperuricemia,can effectively improve renal function,delay the progression of the disease,and has high safety and is worth promoting.

Key words： Chronic kidney disease Hyperuricemia Uric acid lowering Renal function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CAI Li
	CHEN Yao
	WU Ya-li
	LI Peng
	ZHU Wen
	LE Mei-cheng

Cite this article:

CAI Li,CHEN Yao,WU Ya-li, et al. Effect of uric acid therapy on renal function in elderly patients with chronic kidney disease complicated with hyperuricemia[J]. 中国当代医药, 2020, 27(30): 40-42转46.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I30/40

[1]	张路霞，王梅，王海燕.慢性肾脏病的流行病学研究[J].中华肾脏病杂志，2005，21（7）：425-428.
[2]	辛雷，梁菁菁，高颖，等.降尿酸治疗对肾脏保护作用的研究进展[J].中国全科医学，2019，22（17）：2025-2029.
[3]	郭丽环，苏伟海，王健美，等.非布司他对慢性肾功能不全伴高尿酸血症患者肾功能的影响[J].贵州医药，2018，42（5）：53-54.
[4]	美国NKF-K/DOQI 工作组.慢性肾脏病及透析的临床实践指南Ⅱ[M].北京：人民卫生出版社：2005.
[5]	李荣山.慢性肾脏病患者如何降尿酸治疗[J].肾脏病与透析肾移植杂志，2016，25（1）：46-47.
[6]	Sircar D，Chatterjee S，Waikhom R，et al.Efficacy of febuxostat for slowing the GFR decline in patients with CND and asyaptomatic hyperuricemia a 6-month，doublebl ind，randomi zed，placebo-controlled trial[J].Am J Kidney Dis，2015，66（6）：945-950.
[7]	项捷，危静.别嘌醇对高尿酸血症合并慢性肾功能不全患者肾功能的影响[J].中国基层医药，2018，25（19）：2497-2500.
[8]	吕熙，梁利波，唐国华，等.血尿酸对糖代谢异常患者肾功能的影响[J].四川大学学报（医学版），2015，46（5）：754-758.
[9]	黄新忠，薛海燕，袁莉.非布司他对慢性肾脏病3～5期合并高尿酸血症患者的肾脏保护作用及相关机制[J].中国现代医学杂志，2017，27（26）：103-107.
[10]	赵宇飞，程自平，王麟，等.血清尿酸与急性心肌梗死合并慢性肾功能不全患者预后的关系[J].安徽医药，2016，20（7）：1306-1309.
[11]	赵志刚.别嘌呤醇用于治疗慢性肾病合并高尿酸血症的效果观察[J].心理医生，2017，23（4）：57-58.
[12]	Fujimori S，Ooyama K，Ooyama H，et al.Efficacy of benzbrom arone in hyperuricem ic patients associated with chronic kidney disease[J]Nucleosides Nucleotides Nucleic Acids，2011，30（3）：1035-1038．
[13]	曾春艳，乔淑玲，贾春华.别嘌醇联合尿毒清治疗慢性肾功不全高尿酸血症临床观察[J].临床医药文献电子杂志，2016，3（25）：5103.
[14]	祖爽，张森，何舒宁，等.降尿酸治疗对慢性肾脏病2～5期合并高尿酸血症患者肾功能的影响[J].中华肾脏病杂志，2018，34（9）：648-653.
[15]	王惠芳，张伟，李宁，等.非布司他治疗慢性肾脏病3-5期伴高尿酸血症患者的疗效分析及对肾功能的影响[J].中华肾脏病杂志，2017，33（10）：721-728.